Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 51 to 100 of 2013

TitleReference numberPublishedLast updated
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
HIV testing: increasing uptake among people who may have undiagnosed HIVNG60
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Atopic eczema in under 12s: diagnosis and managementCG57
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTG718
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Chronic heart failure in adults: diagnosis and managementNG106
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Bipolar disorder: assessment and managementCG185
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Pneumonia: diagnosis and managementNG250
Tirzepatide for managing overweight and obesityTA1026
Tirzepatide for treating type 2 diabetesTA924
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Compression products for treating venous leg ulcers: late-stage assessmentHTG758
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessmentHTG759
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessmentHTG757
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1088
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Single-step scaffold insertion for repairing symptomatic chondral knee defectsHTG728
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessmentHTG756
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080
One-piece closed bags for colostomies: late-stage assessmentHTG754
Pulsed-field ablation for atrial fibrillationHTG755
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessmentHTG753
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Dapagliflozin for treating chronic kidney diseaseTA1075
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitationHTG752
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessmentHTG751
Spesolimab for treating generalised pustular psoriasis flaresTA1070

Results per page

  1. 10
  2. 25
  3. 50
  4. All